Abstract:Aim: This study aimed to explore the expression pattern of MLLT11 under different pathological features, evaluate its prognostic value for glioma patients, reveal the relationship between MLLT11 mRNA expression and immune cell infiltration in the tumor microenvironment (TME), and provide more evidence for the molecular diagnosis of glioma and immunotherapy. Methods: Using large-scale bioinformatic approach and RNA sequencing (RNA-seq) data from public databases The Cancer Genome Atlas (TCGA), Chinese Glioma Genome Atlas (CGGA), and The Gene Expression Omnibus (GEO)), we investigated the relationship between MLLT11 mRNA levels and pathologic characteristics. The distribution in the different subtypes was observed based on Verhaak bulk and Neftel single-cell classification. Then, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis were used for bioinformatic analysis. Kaplan–Meier survival analysis and Cox regression analysis were used for survival analysis. Correlation analyses were performed between MLLT11 expression and 22 immune cells and immune checkpoints in the TME. Results: We found that MLLT11 expression is decreased in high-grade glioma tissues; we further verified this result by RTPCR, Western blotting, and immunohistochemistry using our clinical samples. According to the Verhaak classification, high MLLT11 expression is mostly clustered in pro-neutral (PN) and neutral (NE) subtypes, while in the Neftel classification, MLLT11 mainly clustered in neural progenitor-like (NPC-like) neoplastic cells. Survival analysis revealed that low levels of MLLT11 expression are associated with a poorer prognosis; MLLT11 was identified as an independent prognostic factor in multivariate Cox regression analyses. Functional enrichment analyses of MLLT11 with correlated expression indicated that low MLLT11 expression is associated with the biological process related to the extracellular matrix, and the high expression group is related to the synaptic structure. Correlation analyses suggest that declined MLLT11 expression is associated with increased macrophage infiltration in glioma, especially M2 macrophage, and verified by RTPCR, Western blotting, and immunohistochemistry using our clinical glioma samples. MLLT11 had a highly negative correlation with immune checkpoint inhibitor (ICI) genes including PDCD1 , PD-L1 , TIM3(HAVCR2) , and PD‐L2 (PDCD1LG2) . Conclusion: MLLT11 plays a crucial role in the progression of glioma and has the potential to be a new prognostic marker for glioma.

Identification of the novel prognostic biomarker, MLLT11, reveals its relationship with immune checkpoint markers in glioma

TREM1 As a Novel Prognostic Biomarker and Tumor Immune Microenvironment Evaluator in Glioma

A Novel Immune-Related Prognostic Biomarker and Target Associated With Malignant Progression of Glioma

Comprehensive analysis of m6A/m5C/m1A-related gene expression, immune infiltration, and sensitivity of antineoplastic drugs in glioma

Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma

Identification of tumor-associated antigens and immune subtypes of lower-grade glioma and glioblastoma for mRNA vaccine development

Novel Immune Checkpoint-Related Gene Model to Predict Prognosis and Treatment Responsiveness in Low-Grade Gliomas

SLC11A1 As a Stratification Indicator for Immunotherapy or Chemotherapy in Patients with Glioma

An m6A/m5C/m1A/m7G-Related Long Non-coding RNA Signature to Predict Prognosis and Immune Features of Glioma

New prognostic biomarker CMTM3 in low grade glioma and its immune infiltration

Identification of N6-Methyladenosine-Related lncRNAs as a Prognostic Signature in Glioma

CMTM Family Genes Affect Prognosis and Modulate Immunocytes Infiltration in Grade II/III Glioma Patients by Influencing the Tumor Immune Landscape and Activating Associated Immunosuppressing Pathways

Development and Validation of a Tumor Mutation Burden–Related Immune Prognostic Model for Lower-Grade Glioma

A Novel Four-Gene Signature Associated With Immune Checkpoint for Predicting Prognosis in Lower-Grade Glioma

Prognosis Analysis and Validation of m6A Signature and Tumor Immune Microenvironment in Glioma

The Systematic Landscape of Nectin Family and Nectin-Like Molecules: Functions and Prognostic Value in Low Grade Glioma

A TGF-β Signaling-Related Lncrna Signature for Prediction of Glioma Prognosis, Immune Microenvironment, and Immunotherapy Response

LCTL is a Prognostic Biomarker and Correlates with Stromal and Immune Infiltration in Gliomas.

Transcription Factor Signatures May Predict the Prognosis and Status of the Immune Microenvironment of Primary Lower-Grade Gliomas

Identification of a Tumor Microenvironment-Related Eight-Gene Signature for Predicting Prognosis in Lower-Grade Gliomas